Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study

被引：8
|
作者：
Rossi, E
Perrone, F
Labonia, V
Landi, G
Nuzzo, F
Amabile, G
Gridelli, C
Di Maio, M
D'Aiuto, G
de Matteis, A
机构：
[1] Natl Canc Inst, Div Med Oncol C, I-80131 Naples, Italy
[2] Natl Canc Inst, Clin Trials Unit, I-80131 Naples, Italy
[3] Civil Hosp, Monteforte, Italy
来源：
ONCOLOGY | 2003年 / 64卷 / 04期
关键词：
D O I：
10.1159/000070313
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：479 / 480
页数：2
相关论文
共 50 条
  • [31] Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: A phase II study conducted by the Hellenic Cooperative Oncology Group
    Nicolaides, C
    Dimopoulos, MA
    Samantas, E
    Bafaloukos, D
    Kalofonos, C
    Fountzilas, G
    Razi, E
    Kosmidis, P
    Pavlidis, N
    ANNALS OF ONCOLOGY, 2000, 11 (07) : 873 - 875
  • [32] Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer
    Xenidis, N.
    Neanidis, K.
    Amarantidis, K.
    Dimopoulos, P.
    Chamalidou, E.
    Pitsiava, D.
    Tentes, A.
    Chatzaki, E.
    Karakitsos, P.
    Kakolyris, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 69 - 73
  • [33] Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer
    N. Xenidis
    K. Neanidis
    K. Amarantidis
    P. Dimopoulos
    E. Chamalidou
    D. Pitsiava
    A. Tentes
    E. Chatzaki
    P. Karakitsos
    S. Kakolyris
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 69 - 73
  • [34] Paclitaxel plus ramucirumab combination therapy as second-line therapy in elderly patients with metastatic advanced gastric cancer: A single-center retrospective study
    Kashiwada, A.
    Nishioka, A.
    Aragane, N.
    Kimura, S.
    ANNALS OF ONCOLOGY, 2019, 30
  • [35] Capecitabine (X) plus vinorelbine (N) as second-line therapy in Chinese patients (pts) with metastatic breast cancer (MBC).
    Xu, B
    Tian, L
    Wu, Q
    Zhou, M
    Wang, H
    Tong, Z
    Li, H
    Li, L
    Hu, G
    Shi, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 73S - 73S
  • [36] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    SPRINGERPLUS, 2014, 3
  • [37] A COMPARISON OF FIRST-LINE TREATMENT WITH GEMCITABINE PLUS DOCETAXEL VERSUS GEMCITABINE PLUS VINORELBINE IN WOMEN WITH METASTATIC BREAST CANCER
    Bensalem, A.
    Bouzid, K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [38] A cost-utility analysis of second-line chemotherapy in metastatic breast cancer - Docetaxel versus paclitaxel versus vinorelbine
    Launois, R
    ReboulMarty, J
    Henry, B
    Bonneterre, J
    PHARMACOECONOMICS, 1996, 10 (05) : 504 - 521
  • [39] A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
    Baur, Martina
    van Oosterom, Allan T.
    Dieras, Veronique
    Tubiana-Hulin, Michele
    Coombes, R. Charles
    Hatschek, Thomas
    Murawsky, Michael
    Klink-Alakl, May
    Hudec, Marcus
    Dittrich, Christian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (02) : 125 - 135
  • [40] A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
    Martina Baur
    Allan T. van Oosterom
    Véronique Diéras
    Michele Tubiana-Hulin
    R. Charles Coombes
    Thomas Hatschek
    Michael Murawsky
    May Klink-Alakl
    Marcus Hudec
    Christian Dittrich
    Journal of Cancer Research and Clinical Oncology, 2008, 134 : 125 - 135
12345